Virpax Pharmaceuticals, Inc. (VRPX)

NASDAQ: VRPX · IEX Real-Time Price · USD
4.261
+0.611 (16.75%)
At close: Mar 28, 2024, 4:00 PM
4.140
-0.121 (-2.84%)
After-hours: Mar 28, 2024, 6:22 PM EDT

Company Description

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.

Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.

Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals logo
Country United States
IPO Date Feb 17, 2021
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Gerald W. Bruce

Contact Details

Address:
1055 Westlakes Drive, Suite 300
Berwyn, Pennsylvania 19312
United States
Phone 610-727-4597
Website virpaxpharma.com

Stock Details

Ticker Symbol VRPX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001708331
CUSIP Number 928251107
ISIN Number US9282511073
Employer ID 82-1510982
SIC Code 2834

Key Executives

Name Position
Gerald W. Bruce Chief Executive Officer and Director
Dr. Jeffrey A. Gudin M.D. Executive Vice President, Chief Medical Officer and Director
Vinay Shah A.C.A., M.B.A. Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. Chief Scientific Officer
Shana Panzarella Chief of Staff

Latest SEC Filings

Date Type Title
Mar 26, 2024 10-K Annual Report
Mar 26, 2024 8-K Current Report
Mar 18, 2024 8-K Current Report
Mar 1, 2024 8-K Current Report
Jan 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 29, 2023 8-K Current Report
Dec 13, 2023 8-K Current Report
Dec 7, 2023 DEF 14A Other definitive proxy statements
Dec 7, 2023 8-K Current Report
Dec 7, 2023 10-Q Quarterly Report